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ABSTRACT  
Objective: This study was aimed to extract Hypoxoside, a water soluble phytochemical, from the corms of Hypoxis hemerocallidea, and incorporate 
it into a suitable transdermal carrier system to increase its penetrability and deep dermal delivery for potential antioxidant and anticancer activity.  
Methods: The extraction of Hypoxis hemerocallidea corms was carried out by continuous hot extraction method. This extract (20 mg/ml) was 
loaded into ethosomal vesicular system by cold method and optimized by varying proportions of lecithin and ethanol. The optimized system was 
then subjected to characterization in terms of particle size, polydispersity index (PDI), entrapment efficiency and invitro permeation and 
penetration studies.  
Results: The optimized vesicle with size of 176.2±11 nm, PDI of 0.231 and entrapment efficiency of 74.2±2.3% was obtained which showed a 
sustained release pattern of the hypoxoside from the vesicular system. Confocal laser scanning microscopy (CLSM) demonstrated that the vesicles 
were able to efficiently traverse the skin to a depth of 117.29 µm whereas the mechanism of vesicle-skin interaction was confirmed by 
histopathological study.  
Conclusion: The study indicated that with the development of an efficient delivery system a water soluble phytochemical with antioxidant and 
anticancer properties can be efficiently delivered to the skin. 
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INTRODUCTION  
Hypoxis hemerocallidea Fisch. (Hypoxidaceae), commonly known as 
hypoxis, African potato, is a plant native to the savanna regions of 
South Africa, Swaziland and Zimbabwe [1, 2]. This herb has been 
widely used in traditional African medicine for centuries for the 
alleviation of numerous diseases exhibiting activities such as anti-
inflammatory, antioxidant, anti-epileptic, antidiabetic, 
antinociceptive, immunomodulatory and anticancer [3-5]. A major 
phyto constituent of this herb, hypoxoside, a norlignan glycoside, 
which though inactive undergoes degradation in the presence of an 
enzyme β-glucosidase, to form an aglycone, rooperol [6]. This 
enzyme, β-glucosidase, is produced 100 folds more in cancer cells 
than in normal cells, thus ensuring specific targeting of the 
cancerous tissue. Rooperol and has been patented in the US as an 
anticancer agent for skin, colon and lung cancer [7]. Cytotoxic 
activity of hypoxoside was found against B16-F10-BL-6 mouse 
melanoma cells in the presence of β-glucosidase, whereas the 
aglycone (rooperol), was found to be cytotoxic per se [8]. The 
modern day practice demands an assimilation of a drug (natural or 
synthetic) into a novel drug delivery system in order to make it 
suitable and successful conduit for targeting drug to desired site. 
Carriers like solid-lipid nanoparticles, nanostructured lipid carriers, 
nano emulsion gels have been suitably used for skin delivery [9-11]. 
More recently, ethanolic vesicular systems called ethosomes with an 
array of advantages have emerged as an acceptable dermal delivery 
tool specifically in skin conditions where the therapeutic 
requirement amounts to targeting drug delivery to deeper skin 
layers [12, 13]. These vesicles are composed of ethanol, 
phospholipid, and water. The presence of ethanol, a well-known 
permeation enhancer provides elasticity to the vesicles as well as 
increases fluidity of the intercellular lipids which in synergism with 
the ability of the vesicular lipids to fuse with skin lipids enhance the 
efficacy of the ethosomal carriers to release the drug in the deeper 
layers of the skin [14]. In addition, these vesicular systems have the 
capacity to load both lipophilic as well as hydrophilic drug. Unlike 
other vesicular systems, ethosomes can better encapsulate hydrophilic 
moieties both in the aqueous core of the ethosomal system as well as 
in the solution form in the ethanol molecules embedded in the lipid 
bilayer. The study, therefore focuses on developing and optimizing a 
model transdermal carrier system for improved loading and enhanced 
delivery of a hydrophilic phytochemical. 
Thus, the objective of the study is to extract hypoxoside from the 
corms of Hypoxis hemerocallidea and formulate an optimized 
ethosomal system encapsulating the extracted bioactive to increase 
its availability to various skin layers serving as a potential tool in 
various skin afflictions. 
MATERIALS AND METHODS 
Chemicals and reagents  
The African Potato corms were obtained from The Swaziland 
Agricultural Research Centre, Malkerns, Swaziland. The corms 4 kg 
were tested by the Phytosanitary Department of the Ministry of 
Agriculture in Swaziland and the identity of the species was 
ascertained as Hypoxis hemerocallidea (Hypoxidaceae). The African 
Potato corms were further authenticated by The National Bureau of 
Plant Genetic Resources (NBPGR), Pusa Campus, New Delhi. Soybean 
phosphatidylcholine (Phospholipon 90 G) was obtained as a gift 
sample from LIPOID, Germany. Ethanol absolute (99.99%) was 
purchased from Changshu Yangquan Chemical, China. Carbopol 934 
was supplied by Ranbaxy laboratories ex-gratia. All other chemicals 
and reagents were from S. D. Fine Chemical, India.  
Extraction of the Hypoxoside: the active phytochemical 
component 
The extraction of Hypoxis hemerocallidea corms was carried out by 
continuous hot extraction method [15]. In the preparation of the African 
Potato extract, the following 3 main procedures were followed:  
Preparation of dried coarse powder of the african potato corms 
The fresh corms (3 kg) were washed properly using tap water. The 
adventitious roots were removed and the outer covering of the corm 
was peeled-off. The fresh corms (2 kg) was cut into small pieces and 
put in an oven at 45 °C for 12 h, with occasional removal from the 
oven every 3 h. Dried coarse powder (800 g) was successfully 
obtained and stored in an airtight container for future use. 
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Extraction of the dried coarse powder with methanol using a 
Soxhlet apparatus 
The dried coarse powder (200 g) was exhaustively extracted with 
methanol (1000 ml) using the Soxhlet apparatus for 36 h to obtain 
the methanolic extract. 
Concentration of the methanolic extract under reduced 
pressure 
The thick methanolic extract was then further concentrated under 
reduced pressure using a rotary evaporator to obtain a viscous dark 
brown residue (170.5 g, 85.25 % yield). The viscous residue was 
stored in refrigerator at 2 °C for further use. 
Enrichment of extract 
The dried extract (100 g) was re dissolved in water (250 ml) and 
partitioned with chloroform (250 x 3). The aqueous layer and the 
chloroform layer were separated and concentrated to dry residue.  
Preparation of ethosomes (Placebo and hypoxoside loaded 
vesicles) 
Ethosomes were prepared by cold method [16]. Briefly, lecithin was 
weighed and dissolved in ethanol. Specific amount of distilled water 
with or without hypoxoside (20 mg/ml) was taken. To this, ethanolic 
mixture was transferred dropwise while stirring at 1000 rpm using 
a magnetic stirrer for 20 min in a closed assembly to prevent 
evaporation of ethanol. The whole assembly was maintained at 30 °C 
throughout the process. The ethosomes so formed were then 
transferred into glass vials and stored in a cool, dry place. In order to 
attain the optimized formulations, lecithin and ethanol 
concentration was taken as independent variables while the PDI, 
particle size and entrapment efficiency were taken as dependent 
variables. Soya lecithin (2, 2.5% and 3%) and ethanol (30, 40, 45%) 
concentration were taken at three different levels. 
Vesicle size and size distribution  
The mean size and polydispersity index of the vesicles were 
analyzed by dynamic light scattering technique also known as 
photon correlation spectroscopy using Zetasizer 1000 HS (Malvern 
instruments, UK) The sample was placed in a quartz cuvette diluted 
with distilled water and size measurements were carried out at a 
scattering angle of 90 °. All observations were recorded in triplicate 
for each formulation.  
Ethosomal characterization  
Vesicular shape and surface morphology  
Scanning Electron Microscopy (SEM) was used to characterize the 
surface morphology of the vesicles. One drop of ethosomal system 
was mounted on clear glass stub, air dried and coated with Polaron 
E 5100 Sputter and visualized under Scanning electron microscope 
(JEOL JSM 840, USA). 
Transmission Electron Microscope (TEM) (Philips, CM-10 model) 
was used as a visualizing aid for vesicles. Samples were dried on 
carbon-coated grid and negatively stained with aqueous solution of 
phosphotungstic acid. After drying, the specimen was viewed under 
the microscope at 10–100 k-fold enlargements at an accelerating 
voltage of 100 KV. 
Entrapment efficiency 
The entrapment efficiency was determined with respect to drug 
concentration of the supernatant. The entrapment efficiency of 
hypoxoside loaded ethosomal formulation was obtained by the 
separation of free drug from that entrapped in the ethosomes by 
ultracentrifugation at 10000 rpm for 40 min at 4 °C. The supernatant 
containing free hypoxoside was collected and analyzed by UV 
spectroscopy at 258 nm. The encapsulation efficiency was calculated 
using equation (1) 
Encapsulation efficiency (%) =  x 100 (1) 
In vitro skin permeation and skin deposition  
The rat was sacrificed by cervical dislocation and the abdominal skin 
was excised. The hair was carefully shaved with the help of a 
depilatory (Veet, Reckitt Benckiser). The fat adhered on the dermal 
side of the skin was removed using isopropanol. The Franz diffusion 
cell with a permeation area and receiver cell volume of 0.636 cm2
The receptor compartment was filled with phosphate buffer solution 
and maintained at 32 °C±1 °C with constant stirring at 100 rpm. The 
upper chamber of the Franz diffusion cell was filled with the 
ethosomal formulation. Sampling was done for 24 h and samples 
were withdrawn through the sampling port at 30 min, 1, 2, 3, 4, 6, 8, 
10, 12 and 24 h and analyzed for drug content by UV spectroscopy at 
258 nm. The receptor cell after each withdrawal was simultaneously 
replenished with an equal volume of fresh phosphate buffer. The 
study was also repeated with hydroethanolic solution of hypoxoside. 
 
and 12 mL, respectively, was set up by mounting the skin on the 
receptor compartment with stratum corneum side facing upwards. 
Drug kinetic modeling  
The drug release profile from the ethosomal vesicles was 
determined by finding the best fit kinetic model amongst: zero 
order, first order, Higuchi and to better determine the release 
behavior Korsemeyer-Peppas model was further applied [17]. 
Depth of skin penetration 
In order to determine the mechanism of penetration of the vesicles 
and their capacity to deliver drug along with its potential to traverse 
skin, confocal laser scanning microscopy, CLSM, was performed. 
Rats were sacrificed and the abdominal skin was removed. The skin 
was treated with Rhodamine B loaded ethosomal vesicles for 24 h 
and then observed under confocal microscope with Fluorescence 
Correlation Spectroscope-Olympus fluo view FV1000 (Olympus, 
Melville, New York) with an argon laser beam with excitation and 
emission wavelength of 488 nm and 590 nm respectively.  
The skin sample was sliced in sections of 6–10 μm thickness through 
the z-axis by CLSM. The results were compared with skin sample 
treated with hydroethanolic solution of the dye.  
Vesicle skin interaction 
The vesicle skin interaction study was done to observe any ultra 
structural changes in the skin upon exposure to the vesicular 
system. The ethosomal formulation (placebo) was applied topically 
on the rat skin for 24hours. After sacrificing the animals by ether 
inhalation, skin was excised and fixed in buffered formalin (10% 
w/v). Sections of skin were stained with haematoxylin and eosin 
stain and observed for histological changes in stratum corneum, 
epidermis and dermis under an optical microscope. An untreated 
skin sample was used as control. 
RESULTS AND DISCUSSION  
Extraction of the hypoxoside 
A viscous dark brown residue was obtained with a percentage yield 
of 85.25 %. The viscous residue was stored in refrigerator at 2 °C for 
further use. The aqueous layer gave a percent yield of 94.46 and 
dissolved majority of the compounds of H. hemerocallidea including 
hypoxoside. This hypoxoside rich fraction used for further studies. 
The chloroform extract gave a meager percent yield of 3.68% and 
consisted mainly of sterols (fig. 1). 
Effect of lecithin and ethanol concentration  
The optimization of the drug loaded ethosomal vesicles were carried 
out by varying the amount of lecithin (2%, 2.5%, and 3%) and 
ethanol (table 1). The result obtained showed that there is a 
correlation between the vesicle size and concentration of lecithin. 
When ethanol was kept as constant, the vesicle size increased with 
increase in lecithin concentration with the smallest vesicle size 
being 176.2±11 (2% lecithin) and the largest of 485.1±20 nm which 
was obtained with 3% lecithin. The particle size obtained for the 
drug loaded formulations ranged from 165.2 to 494.1 nm. 
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However, no significant difference in size was observed with an 
increase in ethanol concentration although the PDI decreased even 
though not in all the cases. Also, increasing the ethanol 
concentration beyond 40% significantly increased the size of the 
ethosomes (data not shown). 
 
 
Fig. 1: It shows (i) Dried Coarse Powder of H. hemerocallidea; 
(ii) Concentrated extract of H. hemerocallidea; (iii) Aqueous 
Fraction; (iv) Chloroform Fraction 
 
This may be possible due to thinning of the vesicle membrane 
resulting in aggregation of vesicles. Entrapment efficiency is a 
measure of suitability of the lipid bilayer of the vesicles to 
incorporate drug. The entrapment efficiency was affected adversely 
with an enhancement in ethanol concentration which was 
responsible for thinning of vesicular membrane allowing only a 
limited amount of drug incorporation.  
The entrapment efficiency was shown to be highest for AP1 with an 
ethanol concentration of 30 %, which also yielded an acceptable size 
and PDI and were submitted for further characterization. 
Surface shape and morphology  
SEM is a dependable tool to ascertain the surface topology of 
vesicular system. The optimized vesicles showed a spherical shaped 
vesicle with a smooth surface as evident in fig. 2A and 2B. The TEM 
microscopy very well corroborated the size of 161.58 nm which was 
close to the one obtained by the zetasizer. (176.2±11 nm). 
In vitro permeation 
The success of any dermal formulation strongly relies on the 
adequate permeation of drug/drug loaded system into the skin; 
hence the first step towards its evaluation remains the in vitro 
permeation studies. The optimized ethosomal preparation revealed 
an in vitro percentage release amounting to 77.61% in 24 h while 
the hydro ethanolic solution of the API showed a permeation of 
70.27% in 12 h (fig. 3). The results indicated the sustained and 
prolonged release behavior of ethosomes which also confirmed the 
presence and retention of ethosomes within the skin tissue. 
Table 1: It shows optimization of ethosomal vesicles showing the effect of independent variables (lecithin and ethanol concentration) on 
dependent variables (vesicle size, PDI and entrapment efficiency) 








PDI Entrapment efficiency  
AP1 2 30 q. s 176.2±11 0.231 74.2±2.3 
AP2 2 40 q. s 194.5±22 0.211 55.6±2.8 
AP3 2.5 30 q. s 262.4±13 0.321 65.21±2.3 
AP4 2.5 40 q. s 285.3±18 0.233 46.32±3.3 
AP5 3.0 30 q. s 485.1±20 0.432 66.88±4.2 
AP6 3.0 40 q. s 452.9±12 0.432 49.34±2.1 
 Values represent mean±SD (n=3) 
 
 
Fig. 2: It shows A) SEM micrographs of optimized formulation AP1; B) TEM micrographs of optimized formulation AP1 
 
 
Fig. 3: It shows comparative release profile of optimized ethosomal formulation (AP1) and hydroethanolic solution of hypoxoside 
(mean±SD, n = 3) 
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Kinetic drug modelling 
Each drug delivery system has a certain mechanism of drug release 
which is ascertained by fitting the drug release profile into standard 
drug kinetic models. The IVR profile of the ethosomal system, when 
subjected to kinetic modeling showed the best fit with zero order 
release model (concentration independent). Further the data was 
fitted into the Korsmeyer-Peppas model and the n value was used to 
determine the nature of drug release.  
Since n value was greater than 0.89 it indicated drug release through 
non-Fickian super case-II transport [18] (table 2 and fig. 4). 
 
Table 2: It shows release rate constants (K), regression coefficient (R2
Zero order 
) and release exponents (n) of optimized ethosomal formulation 
First order Higuichi Korsemeyer-Peppas 
K R K 2 R K 2 R Rel. expo.(n) 2 R2  
3.316  0.987 3.325  0.985 17.28  0.956  0.984  0.994 
 
 
Fig. 4: It shows (A) Zero order (B) First Order (C) Higuchi (D) Korsmeyer-Peppas. Release rate constants (K), regression coefficient (R2
 
) 
and release exponents (n) 
Confocal laser scanning microscopy  
The permeation and retention studies had reflected onto the 
prolonged presence of the ethosomes in the deep skin layers.  
 
 
Fig. 5: It shows CLSM images of cross sections of abdominal rat 
skin after 24-h incubation in Franz diffusion cell A) with 
Rhodamine B loaded ethosomal vesicles; B) with Rhodamine B 
loaded hydroethanolic solution 
 
Fig. 6: It shows Histopathological sections of abdominal skin of 
rat (a) untreated; (b) skin treated with ethosomal vesicles 
 
This entanglement and deposition ensures the suitability of the 
system for delivering the drug into deeper layers of the skin. 
Confocal microscopy successfully showed the penetration of drug 
loaded formulation up to 111.29 µm in z-axis as shown in fig. 5 
which was much higher as compared to that of the hydroethanolic 
solution which reached up to only 17.81 µm. 
Vesicle skin interaction  
The interaction of the ethosomal vesicles with the different layers of 
the skin was demonstrated clearly when the ethosome treated and 
untreated skin samples were examined under the optical 
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microscope. The ethosome treated skin sample showed thinning of 
epidermal layer in contrast to the distinct epidermal and dermal 
layer seen the control skin sample. This indicated the mode of 
ethosomal entry into the skin. Ethanol leads to extraction of the skin 
lipids causing disruption in the stratum corneum layer through 
which the vesicles pass and release the drug in the deeper layers of 
the skin [19]. Also, safety of ethosomal vesicles was established as 
ethanol did not show any signs of edema or irritancy. 
CONCLUSION  
It may be concluded that a popular folklore medicine of African origin, 
sourced from its native place, yielded a potential anticancer 
phytochemical hypoxoside which was successfully assimilated into a 
modern pharmaceutical tool and converted into a nanoethosomal 
preparation which has shown appreciable permeation through the skin.  
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